MARC HOROWITZ to Infant
This is a "connection" page, showing publications MARC HOROWITZ has written about Infant.
Connection Strength
0.121
-
Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). J Clin Oncol. 2005 Jan 20; 23(3):525-31.
Score: 0.021
-
Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy. J Clin Oncol. 1996 Mar; 14(3):901-10.
Score: 0.011
-
A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumors. Cancer. 1995 Jun 01; 75(11):2762-7.
Score: 0.011
-
Benefit from prolonged dose-intensive chemotherapy for infants with malignant brain tumors is restricted to patients with ependymoma: a report of the Pediatric Oncology Group randomized controlled trial 9233/34. Neuro Oncol. 2014 Mar; 16(3):457-65.
Score: 0.010
-
Feasibility and efficacy of preirradiation chemotherapy for pediatric brain tumors. Neurosurgery. 1988 Apr; 22(4):687-90.
Score: 0.007
-
Brain tumors in the very young child. Postoperative chemotherapy in combined-modality treatment. Cancer. 1988 Feb 01; 61(3):428-34.
Score: 0.006
-
Hepatic undifferentiated (embryonal) sarcoma and rhabdomyosarcoma in children. Results of therapy. Cancer. 1987 Feb 01; 59(3):396-402.
Score: 0.006
-
Therapy for childhood soft-tissue sarcomas other than rhabdomyosarcoma: a review of 62 cases treated at a single institution. J Clin Oncol. 1986 Apr; 4(4):559-64.
Score: 0.006
-
The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neuro Oncol. 1999 04; 1(2):152-61.
Score: 0.003
-
Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study. Ann Neurol. 1998 Sep; 44(3):313-6.
Score: 0.003
-
Prognostic factors in infants and very young children with intracranial ependymomas. Pediatr Neurosurg. 1998 Apr; 28(4):215-22.
Score: 0.003
-
Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood. Ultrastruct Pathol. 1997 Jul-Aug; 21(4):369-78.
Score: 0.003
-
Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer. 1996 Aug 01; 78(3):527-31.
Score: 0.003
-
Treatment of infants with malignant gliomas: the Pediatric Oncology Group experience. J Neurooncol. 1996 May-Jun; 28(2-3):245-56.
Score: 0.003
-
Lack of efficacy of postoperative chemotherapy and delayed radiation in very young children with pineoblastoma. Pediatric Oncology Group. Med Pediatr Oncol. 1995 Jul; 25(1):38-44.
Score: 0.003
-
Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med. 1995 Jan 19; 332(3):143-9.
Score: 0.003
-
Postoperative chemotherapy and delayed radiation in infants and very young children with choroid plexus carcinomas. The Pediatric Oncology Group. Pediatr Neurosurg. 1995; 22(4):189-96.
Score: 0.003
-
Desmoplastic infantile gangliogliomas: an approach to therapy. Neurosurgery. 1994 Apr; 34(4):583-9; discussion 589.
Score: 0.002
-
Malignant schwannoma with melanocytic and neuroepithelial differentiation in an infant with congenital giant melanocytic nevus: a complex neurocristopathy. Hum Pathol. 1993 Dec; 24(12):1371-5.
Score: 0.002
-
A phase II evaluation of thiotepa in pediatric central nervous system malignancies. Cancer. 1993 Jul 01; 72(1):271-5.
Score: 0.002
-
Response of pediatric low grade gliomas to chemotherapy. Pediatr Neurosurg. 1993 May-Jun; 19(3):113-8; discussion 119-20.
Score: 0.002
-
Cytogenetic studies in subgroups of rhabdomyosarcoma. Genes Chromosomes Cancer. 1992 Nov; 5(4):299-310.
Score: 0.002
-
Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988. Semin Oncol. 1989 Feb; 16(1 Suppl 3):51-5.
Score: 0.002
-
Challenges in the treatment of childhood fibromatosis. Arch Surg. 1987 Nov; 122(11):1296-8.
Score: 0.002
-
Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep. 1987 Feb; 71(2):131-5.
Score: 0.002